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ABSTRACT

Florida is one of two states that do not allow ARNPs to prescribe controlled substances.
The Florida Legislature has expressed concern regarding the safety of ARNPs prescribing
controlled substances. The purpose of this study was to compare malpractice rates of ARNPs and
physicians in states with and without controlled substance prescribing.
The design was a direct comparison of malpractice rates in states with and without ARNP
controlled substance prescriptive authority. Comparison of malpractice claims was made
between physicians (MDs and DOs collectively) and ARNPs in the United States and by state
ARNP prescribing authority. Comparison of malpractice claims was also made between Florida
and states that were demographically similar.
The results showed that ARNPs have significantly less malpractice than physicians in the
United States. In addition, there were no significant differences in malpractice, whether or not
the ARNP was allowed to prescribe controlled substances. Finally, ARNPs working in states that
are demographically similar to Florida, but allowed to prescribe controlled substances had no
significant increase in malpractice.
This study showed that there is no increase in malpractice rates in states where ARNPs
prescribe controlled substances, either fully or partially, supporting the hypothesis.
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CHAPTER 1: INTRODUCTION/SCOPE OF THE PROBLEM

Nurse practitioners have been in clinical practice for over 40 years and have experienced
expanded privileges to their practice. A total of 48 states now allow Advanced Registered Nurse
Practitioners (ARNPs) at least partial controlled substance prescribing privileges and 34 states
grant ARNPs full prescriptive privileges for Class II-V controlled substances without restrictions
(Byrne, 2008). Full prescriptive privileges have promoted practice autonomy for ARNPs and
access to care and services for clients. While the advances in prescriptive practices have
occurred in 48 states, the State of Florida has not permitted its ARNPs to practice at their full
potential (Miller, 2005). The purpose of this study is to compare malpractice rates of ARNPs
and physicians in states with and without controlled substance prescribing.

Definition of Terms
For the purposes of this study, each term will be defined by their conceptual and
operational meanings. Conceptual definitions express the idea of the term (Rogers & Knafl,
2000). Walker and Avant’s meaning of an operational definition (as cited in Rogers, 2000) are
ways in which the concept can be measured.
Malpractice
Conceptual: Any act or omission by a provider during patient treatment that deviates from
accepted standards of care and causes injury to a patient (Bal, 2009).
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Operational: Physician or ARNP who have committed an error and declared responsible for the
error, such as delay of appropriate care.
Malpractice Rate
Conceptual: Number of occurrences that providers have been accused of malpractice.
Operational: Rates listed in the National Practitioner Data Bank (NPDB) which indicates the
number of malpractice payment reports by state.
Incident
Conceptual: Events in healthcare which may cause unanticipated harm to a patient (Farlex,
2009).
Operational: Inappropriate medication prescribed, illegal dispensing of controlled substances, or
an incident which did not involve medications, such as an incorrect or missed diagnosis.
Controlled Substances
Conceptual: Those medications which have a certain degree of addictive properties and are
regulated by the DEA (Drug Enforcement Administration).
Operational: Medications such as narcotics, barbiturates, and sedatives.
Full Prescriptive Authority
Conceptual: ARNPs are allowed by law to prescribe Class II-V controlled substances
independent of physician involvement. Physicians may be involved in terms of collaborative or
supervisory practice in general terms.
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Operational: Patient requires a Class II medication such as Methylphenidate for Attention
Deficit Hyperactivity Disorder and the ARNP prescribes for the patient without involving the
physician.
Partial Prescriptive Authority
Conceptual: ARNPs are limited by law in prescribing Class II-V controlled substances. This may
be a limitation by class, indication, or quantity.
Operational: The ARNP is allowed to prescribe only a seven-day supply of a Class II
medication. Patients who require controlled substances may need a physician involved in their
care.
No Prescriptive Authority
Conceptual: ARNPs are not allowed to prescribe controlled substances medications.
Operational: Patients who require medications such as a medication for sleep must have a
physician involved in their care.
Supervising Physician
Conceptual: physician (Medical Doctor or Doctor of Osteopathic Medicine) that has a
collaborative protocol agreement with an ARNP (Florida Department of Professional Regulation
Board of Nursing, 1990).
Operational: A physician that accepts responsibility to oversee an ARNPs practice.
Controlled substances are grouped into the following five classes by the Drug
Enforcement Administration (DEA) (Drug Enforcement Administration, 2008). Class I
3

prescriptions are highly addictive and highly abusive substances, and are illegal to prescribe in
the United States (U.S.). Class II prescriptions are those which have a high potential for abuse
and physical dependence. Included in this group are prescriptions for Attention Deficit
Hyperactivity Disorder and severe pain. Class III prescriptions can cause moderate or low
physical dependence or high psychological dependence. Class III medications are generally
prescribed for moderate to severe acute pain. Class IV prescriptions have a low abuse potential
and limited potential for physical or psychological dependence. Class IV medications are
generally prescribed for sleep and anxiety. Class V medications have a low abuse potential, and
may or may not require a prescription. Class V medications include certain cough medicines,
seizure medicines, and anti-diarrheal medications.
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CHAPTER 2: SYNTHESIS OF THE RESEARCH EVIDENCE

In 1977, the first proposal for a Scope of Practice for Advanced Practice Nurses in
Florida was created by a Joint Committee of members from the Florida Department of Health
Boards of Medicine and Nursing (Lumpkin, 2004). In 1979, the Advanced Registered Nurse
Practitioner (ARNP) was defined and added to the Florida Nurse Practice Act. Included in the act
was the requirement that each ARNP would have a supervising physician who would also be
legally responsible for the care and treatment provided by the ARNP. This supervising physician
would establish protocols with the ARNP that delineate the scope of practice with the
supervising physician. The protocols are then submitted to the Boards of Nursing and Medicine,
with bi-annual updates (Florida Department of Professional Regulation Board of Nursing, 1990).
Florida was one of the first states to pass legislation to regulate advanced nursing practice. In
1987, the Joint Committee again convened and authorized ARNPs to prescribe non-controlled
substances (Lumpkin, 2004).
By 1988, ARNPs were working with their supervising physicians to update protocols to
include non-controlled substance medications. In 1995, an ARNP task force was assembled to
develop a bill which would allow nurse practitioners the ability to prescribe controlled substance
medications. The bill was opposed by both the Florida Pharmacy Association and the Florida
Medical Association and was defeated (Lumpkin, 2004). There were several issues which
contributed to the bill’s defeat. One of the issues identified was the allowance of nurse
5

practitioners to gain ARNP licensure through a certificate without additional education. In
addition, there was a nursing movement nationally to standardize basic as well as advanced
educational preparation. The Florida Nurses Association (FNA) began working on minimum
education requirements to facilitate a future bill for advancing ARNP scope of practice. In 1996
a law was passed that changed the minimum education requirement of ARNPs to be a master’s
degree in advanced practice nursing beginning in 1998 (Lumpkin, 2004).
In 1997, the Florida Legislature mandated the creation of a task force appointed by the
Agency for Healthcare Administration to include pharmacists, nurses, physicians and doctors of
osteopathy, as well as a Florida Hospital Association representative. The Prescribing of
Controlled Substances task force was developed to evaluate the risk and benefits of ARNPs
prescribing controlled substance medications in Florida. Their study concluded that ARNPs are
safe to prescribe controlled substance medications (Prescribing of Controlled Substances Task
Force, 1997). This conclusion was based on the findings that the potential for harm to patients or
increase in substance abuse by ARNPs was very limited. In addition, trends of malpractice
payments indicated that in the three years following the Drug Enforcement Agency (DEA)
authorization of “mid-level providers” [sic] to be granted DEA numbers, there was a 5% increase
in malpractice claim awards payments for physicians but a 22% decrease in malpractice claim
awards payments for ARNPs (Prescribing of Controlled Substances Task Force, 1997). There
was dissent, however among the physicians in the group, who wrote a Minority Report,
expressing four primary concerns. The first concern was that there were no studies available
6

regarding the safety of controlled substance prescribing by ARNPs. The second concern was
that many states had limitations on controlled substance medication prescribing. The third
concern was that education was lacking in specific pharmacology training. The fourth and final
concern was that to have ARNPs prescribing controlled substance medications would result in an
increase in the liability exposure for the supervising physician. At the time of the 1997 study, 32
of 50 states had passed legislation to allow ARNPs to prescribe at least some form of controlled
medications. Unfortunately, between 1997 and 2001, the Florida Legislature continued to
oppose allowing ARNPs to prescribe controlled substance medications (Lumpkin, 2004). As
recently as December, 2008, the Florida Senate’s Committee on Health Regulation met to hear
Interim Report 2009-117 which was a report reviewing ARNP prescriptive authority (The
Florida Senate, 2008). The Senate professional staff recommended extending controlled
substance prescribing authority to Florida licensed ARNPs who have attained national
certification. One senator again brought up the safety of ARNPs prescribing controlled
substances and directly asked about malpractice rates in other states that allow ARNPs this
authority. No study to-date had occurred. Of the seven senators present, Senators Michael
Bennett, Dennis Jones and Minority Leader Alfred Lawson were in favor of moving the bill
forward, Senator Dave Aronberg was in favor of allowing ARNPs to prescribe class III-V,
Senators Eleanor Sobel and Thad Altman were opposed, questioning whether there were any
studies on the safety of ARNPs prescribing controlled substances, and Senators Andy Gardiner
and Don Gaetz were silent on the matter. Since consensus could not be reached, the bill was put
7

forth by Senators Bennett and Jones, but the bill was never heard on the floor (Senate Committee
on Health Regulation, 2008). Then in the 2010 legislative session the head of the House of
Representatives Health Care Regulation Policy Committee, Representative Nick Thompson
stated that he would not accept any scope of practice bills this session (Small, 2010).
Patients, ARNPs, and physicians in the state of Florida are faced with many challenges as
a direct result of ARNPs not having full prescriptive authority. Challenges include lost
productivity of the ARNP waiting for a physician to write a prescription, delay of care for the
patient, lost productivity of the physician to leave his own patient to care for the ARNPs
patient’s needs, and increased liability for the physicians to write prescriptions for patients with
whom they are less familiar (Kaplan & Brown, 2004). If the physician is not available, the
patient must arrange a second appointment specifically with the physician to obtain the
appropriate medication. The cost for a patient to make a return visit impacts the patient by
increased time taken from other activities and delay of treatment. A return visit also impacts the
insurance providers, as there will be a second office visit charge (Kaplan, 2004). Patients in
rural areas are most vulnerable to these types of consequences, due to physician shortages
(Ricketts & Holmes, 2007; Hill, 2008; Millson, 2008). ARNP managed clinics in rural and
underserved areas cannot provide patients appropriate services without the ability to prescribe
the medications needed for treatment of the condition. ARNPs also have obstacles when
practicing in specialty practices such as palliative care and pain management, negatively
impacting the patient’s quality of life and comfort. In addition, ARNPs prescribing trends are not
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accurately reflected when a physician must write a prescription for the ARNP’s patient. For
example, an ARNP’s patient requires a medication for anxiety prior to a procedure (such as a
Magnetic Resonance Imaging [MRI]). The protocol for the office is lorazepam, a Class IV
controlled substance. The physician must write the order, making the number of controlled
substances for his/her patient population falsely high, while the ARNP’s record shows none.
Regulations which limit the ARNPs scope of practice, including prescribing controlled
substances, reduce their ability to meet patient’s health care needs (Lugo, O’Grady, Hodnicki, &
Hanson, 2007).
The Florida Legislature has expressed concern regarding the safety of ARNPs being
given the privilege of prescribing controlled substances. This is in direct opposition to the report
written by the professional staff of the Committee on Health Regulation, which stated that
ARNPs pose no greater risk to patients by prescribing more inappropriately than other providers
who have this authorization. Two Senators expressed their own concerns. One concern was
increased prescription drug abuse in Florida and the other is that there is no evidence on
malpractice incidence in controlled substance prescribing (The Florida Senate, 2008). A recent
study evaluated the extent of illicit drug use in the U.S. Drugs included categories of both illegal
substances (heroin, marijuana, and cocaine) and prescription substances used for non-medical
purposes (narcotic pain relievers, tranquilizers, sedatives and stimulants). The Table I shows the
rate of illicit drug use in 2007 comparing U.S. regions (Substance Abuse and Mental Health
Service Administration, 2008).
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Table 1: Illicit Drug Use in Persons over 12
U.S. Region
Percent of persons older than age 12 using illicit
drugs
West
Midwest
Northeast
South

9.3%
7.9%
7.6%
7.4%

Substance Abuse and Mental Health Service Administration, 2008

There have been over 50 studies which have evaluated outcomes, patient satisfaction, and
differences in practice patterns between ARNPs and physicians, but in no study has malpractice,
negative licensure actions, civil judgments, or criminal convictions data been compared for
physicians and ARNPs (Action for Sick Children, 1999; Chumbler, Geller, & Weier, 2000;
Shell, 2001; Jacobs, 2005; Cipher, Hooker, & Guerra, 2006). Therefore this study seeks to
address whether the actual difference in the scope of practice of controlled substance prescribing
of ARNPs affects malpractice judgments, negative licensure actions, civil judgments, and
criminal convictions.
Cumulative Index to Nursing and Allied Health Literature (CINAHL) and MEDLINE
databases were used to complete the literature review for this study. Initial search terms included
Prescribing and Malpractice and ARNP. This produced no results. The second search included
Prescribing Controlled Substances and ARNP or Advanced Practice Nurse. Restrictions were
then placed to include English only. This search produced a yield of 2,167 articles. The third
search included the terms Nurse Practitioner and Prescribing or Malpractice. This produced a
10

yield of 137 articles. There were no peer reviewed data-based research articles which compared
the prevalence of malpractice between ARNPs and physicians. Included in the literature review
were those articles which evaluated the safety of care provided by ARNPs in comparison to
physicians, articles identifying barriers to ARNP practice, including controlled substance
prescribing and articles assessing whether care provided by ARNPs is cost-effective.
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Table 2: Controlled Substance Prescribing Literature Review
CINAHL and MEDLINE Database
Key Words/Limits
Prescribing, ARNP, Advanced Practice Nurse; Limitations: English Only;
No Limit to Dates of Articles

Articles
2167

Prescribing, ARNP, Advanced Practice Nurse. Date Limits set from 2006 to
2008

1,650

Prescribing Controlled Substances, ARNP, Advanced Practice Nurse. Date Limits
2006-2008

940

Nurse Practitioner, Prescribing or Malpractice

137

There have been over 50 studies comparing care and treatment of patients between
ARNPs and Physicians. These studies consistently support that care and outcomes are similar
between the providers (Haider, 2008; Horrocks, Anderson & Salisbury, 2002; Brown and
Grimes, 1995). In a review of prescriptive practices of psychiatrists and psychiatric nurse
practitioners, there were no significant differences in patient adherence to medications (Jacobs,
2005). Significant differences were found in physician’s utilization of more second generation
antidepressants and anxiolytics than the ARNPs who provided more first generation and generic
medications when appropriate.
In terms of time spent with the patients, the ARNPs had increased face-to-face visit time
with patients and they used more integrated therapy, such as biofeedback and psychotherapy
(Jacobs, 2005). One study found that patients perceived nurses to be more approachable when
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medications were needed and that since the ARNP could prescribe the medicine, treatment could
be started sooner rather than waiting for a physician to prescribe. Specifically, patients stated that
they had established a relationship with their nurse, and felt that the ARNP knew more about
their condition than a physician who didn’t know their background (Luker, 1998). ARNPs and
physicians also experience similar difficulties ensuring patient safety in prescribing whether
prescriptive authority is limited or full, such as patient expectations regarding medication, self
adjusting medication and abuse (Jacobs, 2005). Since the ARNP has been shown to provide
patients with more education regarding care and treatment, the risk should not increase, but be
equivalent or possibly decrease (Little, 2001).
In a study by Cipher (2006), there were increases in the amount of controlled substance
prescribing among ARNPs from 1996-2002, compared to the seven years prior, however over
the time of the study more and more states were passing laws allowing ARNPs to either
prescribe controlled substances, or expand the degree to which they were allowed to prescribe
controlled substances.
The Florida Medical Association in its Minority Report to the Florida Legislature
brought up the concern of increased liability exposure to the supervising physician if ARNPs are
allowed to prescribe controlled substances (The Joint Committee Task Force, 1997). The term
“supervising physician” can allow a lawsuit to expand, and even those with appropriate practice
can receive a lawsuit, but if the physician has never seen the patient, nor been asked his/her
advice, then the physician as a defendant in the suit would be most likely dropped (Buppert,
13

2001). The case, however, becomes more complicated with current restrictions on prescribing for
ARNPs. Consider that the ARNP’s patient requires a controlled medication, such as a refill on a
Class II drug for Attention Deficit Hyperactivity Disorder (ADHD). The nurse practitioner must
obtain the controlled substance prescription from the physician and give it to the patient. The
physician did not evaluate the patient and yet the physician’s name must be on the prescription
for the medication. This leads to not only increased liability for the physician who is now
responsible for the outcome, but inappropriate tracking of prescribing trends in all states with
limitations (Lebo, 2007). Poor outcomes alone, however, are not the only reason that persons
bring about a lawsuit, but lapse in communication following the occurrence is a major issue
(Baum & Dowling, 2009). Communication is one area that nurse practitioners have improved
skills compared to physicians. In a meta-analysis by Haider, surveys indicated patients preferred
ARNPs due to the increased time spent in communication with the patient (Shum, Humphreys,
Wheeler, Cochrane, Skoda, & Clement, 2000; Haider, 2007). In the same meta-analysis, mothers
of sick children expressed that family physicians made them feel anxious, and gave them vague
instructions for care (Haider, 2007, Action for Sick Children, 1999). More recently, a nurse
practitioner managed cardiac clinic at the Cleveland Clinic was designed to address the needs of
heart patients in terms of improving health outcomes as well as preventive care. Surveys were
conducted monthly to assess the quality of the program as this was originally managed by
physicians. After one year, the clinic was found to be cost-effective, had improved patient
satisfaction scores in the areas of communication and spending enough time with the patient, and
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improved outcomes including significant reductions in total cholesterol, triglycerides, highdensity lipoprotein, low-density lipoprotein, blood pressure, and C-reactive protein (Gambino,
Planavsky, & Gaudette, 2009). Studies consistently show that ARNPs can effectively reduce
healthcare costs while maintaining quality, improving communication and improving outcomes.
In Barriers to Autonomous Practice, Kaplan (2004) studied specific barriers to
prescriptive authority with controlled substances II-V and grouped ARNPs into those with full
authority and those without authority in the State of Washington. The study questioned the
ARNPs before the law authorizing prescriptive authority for Class II-IV was in place and again
soon after the law was enacted. Findings revealed that the ARNPs primary reason for not
pursuing DEA registration and prescriptive authority were lack of expertise in prescribing
specific Schedule II-IV drugs. The author continued to follow the same ARNPs over a two year
period and found that by year two, two-thirds of the ARNPs had obtained DEA licenses and
were prescribing controlled substances. One premise as to why the ARNP did not wish to
prescribe controlled substances reported a concern regarding patients with drug-seeking behavior
(Kaplan, 2004). These findings both support the requirement for pharmacology education for
ARNPs with regards to controlled substance prescribing (Kaplan, 2004).
State limitations have also imposed barriers to practice, limiting the ARNP’s ability to
practice to their fullest capacity (Pan, Straub & Geller, 1997). Rankings of states related to
ARNP autonomous practice (including prescriptive authority) were published to show the

15

disparity of scope, despite standardized training. In this study, Florida ranked 49th out of 51
states including the District of Columbia (Lugo, 2007, Phillips, 2009).
Recently, several national advanced practice nursing groups have united to create a
Consensus Model for Advanced Practice Registered Nurse (APRN) regulations: Licensure,
Accreditation, Certification and Education (Trossman, 2008). This document was created and
endorsed by several advanced practice specialist or specialty groups, including nurse-midwives,
clinical nurse specialists, and nurse practitioners to standardize the education and regulatory
processes for APRN practice and promote APRNs independent function, including prescriptive
authority (Trossman, 2008).
Cost savings is another advantage to allowing ARNPs full prescriptive authority. In a
recent cost-benefit analysis, a net benefit of $32 million dollars in the state of Florida per year
was estimated (Chandler, 2007). Cost estimates included time for the practitioner to find the
physician, the physician to stop his patient flow to prescribe the medication, and those instances
where a second office visit would be required, should the physician not be in the office at the
time (Chandler, 2007). Nurse practitioner managed clinics (NMCs) are also a way to improve the
cost of healthcare. Coddington & Sands (2008) conducted a meta-analysis describing five NMCs
as having significant impact on reduced emergency department, urgent care centers and
hospitalization visits. This is enhanced by providing preventive services to persons who could
otherwise not afford treatment. In one study, Schroeder (1993) estimated over $750,000 in
savings was found by ARNP care in reducing the number of HIV patients hospitalizations and
16

the following year, over one million dollars savings was realized. Another study evaluated a
NMC, and found that some months after opening, the local emergency department found that the
NMC’s clients were only making up 0.3% of overall visits (Helvie, 1999). A thirteen million
dollar savings occurred in another hospital following a NMC opening, by a 25% reduction in
emergency department visits (Smith-Campbell, 2005).
In conclusion, there are over 50 studies which compare care and treatment between
ARNPs and Physicians but none which specifically look at comparing the prevalence of
malpractice claims in states with and without ARNP controlled substance prescribing privileges
regulation.
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CHAPTER 3: PROJECT IMPLEMENTATION

The purpose of this study was to identify any difference in malpractice rates among
ARNPs and physicians in states with either full or partial controlled substance prescriptive
authority. The data was reported from the National Practitioner Data Bank as cumulative
malpractice claims for each state (Pearson, 2010). Specific data regarding malpractice rates
secondary to controlled substance prescribing was not available. The physician’s rates were
calculated as Medical Doctor (MD) malpractice rates and Doctor of Osteopathic Medicine (DO)
malpractice rates combined. This design was chosen to provide a direct comparison of
malpractice rates in states with and without ARNP controlled substance prescriptive authority.
Various studies have been conducted that compare outcomes, practice patterns, and cost
effectiveness of ARNPs utilizing a full scope of practice, but no studies have specifically looked
at prescriptive authority and malpractice rates.
The population for this project included all ARNPs and physicians in all of the U.S. and
the District of Columbia. Data regarding total population for each classification was derived
from the Pearson Report (Pearson, 2010). Rates of malpractice were obtained from the National
Practitioner Data Bank Summary Report and the National Practitioner Data Bank 2006 Annual
Report (Pearson, 2010). Information regarding adverse action reports, civil judgments, and
criminal conviction reports was obtained from the Healthcare Integrity and Protection Data Bank
(Pearson, 2010). For this study, several sources were evaluated for the most accurate
18

determination of malpractice data. The closest data set to reflect malpractice data in the United
States is the National Practitioner Data Bank. This information, however, is not complete in
itself. Actions restricting clinical privileges and professional society membership sanctions are
mandatorily reported for physicians and dentists but are voluntarily reported for other providers
to include ARNPs (National Practitioner Data Bank, 2006). Malpractice reports are also skewed
in that some providers may have had two or more malpractice suits which inappropriately
worsen rates for the entire provider group. In addition, the National Practitioner Data Bank
reports cumulative data from 1990-2008, and not annual rates. Finally, states have granted
controlled substance prescriptive authority to ARNPs in various years, which may make some
states malpractice rates with earlier legislation related to controlled substance prescribing more
accurate than those states that have changed prescriptive authority in more recent years.
Therefore, other sources for data were included and are presented in the following table.
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Table 3: Sources for Data Collection
Agency
Data to be Collected
Federal Drug Enforcement Agency (DEA) Case reports of DEA intervention against providers who
have been sanctioned in some way related to controlled
substance prescribing.
Health Integrity Protection Data Bank

Number of reports concerning individuals by professional
type and by Federal Licensure and DEA Action

Kaiser Foundation

State health facts concerning number of practitioners in
each state and demographic characteristics of the
professions in the state.

National Practitioner Data Bank

Number of malpractice cases by provider type and state
which resulted in payment.

Pearson Report

Overall prevalence of malpractice rates in each state by
professional type.

Design
This study was conducted as a secondary analysis of collected data regarding malpractice
rates among ARNPs and physicians. The design was chosen after an extensive search of other
sources for specific information regarding malpractice related to controlled substance
prescribing. The Drug Enforcement Administration tracks and presents specific cases of misuse
of controlled substances rather than aggregate data. The Health Integrity Protection Data Bank
tracks the number of adverse events, criminal convictions and civil judgments against
practitioners, but is only mandated for MDs and DOs and voluntarily reported by ARNPS. There
was also investigation of insurance companies that carried malpractice insurance for physicians
20

and ARNPs to assess whether controlled substance prescribing increased the risk, and therefore
the rate of insurance, versus a provider that did not prescribe controlled substances. It was
discovered, however, that controlled substance prescribing was only a small part of a larger
complex formulation in determining annual malpractice insurance rates. No source was found
that monitored malpractice as it relates to controlled substance prescribing by state. The closest
source that monitored overall malpractice by state was the National Practitioner Data Bank.
Human Subjects
There was no risk to human subjects. All of the data collected was public domain and has
been reviewed by other methods to describe specific trends. The University of Central Florida
Institutional Review Board reviewed this study and determined that the proposed study was not
human research and thereby exempt from IRB review (see Appendix).
Data Analysis
Data was analyzed using the SPSS Database system. Frequency distributions were
performed for each of the research questions.
In this study, each state was listed in the data spreadsheet. All 50 states including the
District of Columbia were coded according to the level of ARNP controlled substance
prescribing regulations: full, partial, or none. Each state then had listed the total number of
ARNPs practicing in the state as well as the total number of MD’s, DO’s and combined
physicians practicing in the state. Finally, malpractice rate by provider type (ARNP, MD, and
DO) for each state was analyzed.
21

The research questions for this study included the following:
•

What was the rate of malpractice claims by state against ARNPs compared to physicians
in the U.S.?

•

What was the rate of malpractice claims against ARNPs compared to physicians in states
in which ARNPs have full controlled substance prescribing privileges?

•

What was the rate of malpractice claims against ARNPs compared to physicians in states
in which ARNPs have partial controlled substance prescribing privileges?

•

What was the rate of malpractice claims against ARNPs compared to physicians in states
in which ARNPs do not have controlled substance prescribing privileges?

•

Was there a difference in the rate of malpractice among ARNPs based on prescriptive
authority?

•

Was there a difference in ARNP malpractice rates in Florida compared to states
demographically similar to Florida but allowing controlled substance prescribing?
Statistical evaluation included frequency distributions, mean distribution, one-sample t-

test, Wilcoxon Signed Ranks test, and the Kruskal-Wallis test. Graphic representation of the data
was also utilized. Independent variables included the number of ARNPs nationally and in each
state, the number of physicians nationally and in each state, and ARNP prescribing privileges.
Dependent variables included the rate of malpractice per 1000 per discipline, and the rate of
malpractice in each state. States were then coded as determined by the level of autonomy nurse
practitioners have to prescribe controlled substances (full prescribing, partial prescribing and no
22

prescribing). The hypothesis was that there was no statistically significant difference in the
malpractice rates of ARNPs and physicians in states with and without controlled substance
prescribing.
There are a number of limitations inherent in this study. Data collected regarding
malpractice was not equal among providers. There were only two professions that required
mandatory reporting for malpractice incidents with the National Practitioner Data Bank,
physicians and dentists. In addition, malpractice rates do not specifically represent malpractice
related to controlled substance prescribing. Malpractice payment reports also do not distinguish
those providers who have had one malpractice claim or several. This can affect the overall rate of
malpractice as well. The available data can only be interpreted as to whether there is evidence
that ARNPs in states with controlled substance prescribing have overall significantly more
malpractice judgments against them compared to ARNPs in states without controlled substance
prescribing.
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CHAPTER 4: RESULTS

In this chapter, the findings of the data analysis are presented. The sample for the study
included data for the 50 United States and the District of Columbia. Data collected from each
state included numbers ARNPs, DOs and MDs by state, malpractice rates by state, adverse
actions, civil judgments and criminal convictions reports, and level of state ARNP prescribing
privileges. For malpractice rates, data was analyzed by malpractice rate per 1000 providers for
each set and then compared. Comparison results to address the research questions were as
follows:

Question 1:

What was the malpractice rate for ARNPs compared to physicians in the United

States?
There were 156,958 ARNPs in the U.S, (mean [M] = 3,078 per state; Median [Mdn] = 2,319 per
state). The average or mean rate of malpractice for every 1000 ARNPs was 6.29. There were
over 978,672 physicians in the U.S (M = 19,190 per state, Mdn = 11,829 per state). The average
or mean rate of malpractice for every 1000 physicians was 249.75. The results of the Wilcoxon
signed rank test indicated that nurse practitioners (Mdn = 5.28) have statistically significant
lower malpractice rates than physicians (Mdn = 247.75) (p<.001).
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Figure 1. Comparison of Malpractice Rates for Physicians and ARNPs

Question 2:

What was the rate of malpractice claims against ARNPs compared to physicians

in states in which ARNPs have full controlled substance prescribing privileges?
There were 34 states including the District of Columbia that allow ARNPs full prescriptive
authority. The number of ARNPs in states with full prescriptive authority totaled 93,083. In the
same states there were 565 malpractice claims. The average or mean rate of malpractice for
every 1000 ARNPs in states with full prescriptive authority was 7.00. The number of physicians
in states where ARNPs have full prescriptive authority was 552,461. In those same states there
were 133,995 malpractice claims against physicians. The average or mean rate of physician
25

malpractice in states with ARNP full prescriptive authority for every 1000 physicians was
234.97. The results of the Wilcoxon signed rank test indicated that malpractice rates against
ARNPs in states with full prescriptive authority (Mdn = 6.21) have statistically significant lower
malpractice rates than physicians (Mdn = 222.63) in those states (p<.001).

Question 3:

What is the rate of malpractice claims against ARNPs compared to physicians in

states in which ARNPs have partial controlled substance prescribing privileges?
There are 15 states that allow ARNPs partial prescriptive authority. The number of ARNPs in
states with partial prescriptive authority was 50,804. The average or mean rate of malpractice for
every 1000 ARNPs in states with partial prescriptive authority was 4.48. The number of
physicians in states where ARNPs have partial prescriptive authority was 356,136. In those same
states there were 107,439 malpractice claims against physicians. The average or mean rate of
physician malpractice in states where ARNPs have partial prescriptive authority for every 1000
physicians was 288.47. The results of the Wilcoxon signed rank test indicated that malpractice
rates against ARNPs in states with partial prescriptive authority (Mdn = 3.73) have statistically
significant lower malpractice rates than physicians (Mdn = 262.74) in those states (p<.001).

Question 4:

What is the rate of malpractice claims against ARNPs compared to physicians in

states in which ARNPs do not have controlled substance prescribing privileges?
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There are two states that did not allow controlled substance prescriptive authority. The number
of ARNPs in states that do not allow controlled substance prescriptive authority was 13,071. The
average or mean malpractice rate for every 1000 ARNPs in states that do not have controlled
substance prescriptive authority was 7.94. There were 70,075 physicians in states in which
ARNPs do not have controlled substance prescriptive authority. The average or mean
malpractice rate for every 1000 physicians in states where ARNPs do not have controlled
substance prescriptive authority was 210.46. The results indicate that ARNPs have lower
malpractice rates than physicians in states that do not allow ARNP controlled substance
prescribing.

Question 5:

Is there a difference in the rate of malpractice among ARNPs based on

prescriptive authority?
Statistical analysis was performed using the Kruskal-Wallis test to evaluate significant
differences in malpractice rates for ARNPs in states with full, partial and no prescriptive
authority. The average or mean malpractice rate for every 1000 ARNPs in states with full
prescriptive authority was 7.00. The average or mean malpractice rate for every 1000 ARNPs in
states with partial prescriptive authority was 4.48. The average or mean malpractice rate for
every 1000 ARNPs in states without controlled substance prescriptive authority was 7.94. The
results of the Krukal-Wallis one-way ANOVA by ranks indicated that there were no statistically
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significant differences among the three prescribing privilege categories (χ²K-W=4.304, df=2,
p=.116).

Table 4: Summary of Malpractice Rate/1000 by ARNP Prescribing Privileges
Controlled Substance
Prescribing Authority

Number of
States (n)

Number of
ARNPs

Full Prescriptive
Authority

34

Partial Prescriptive
Authority
No Prescriptive
Authority

Question 6:

Number of
Physicians

Mean/ Median
Per State

93,083

Mean/
Median
Per State
7.00/6.21

552,461

234.97/222.63

15

50,804

4.48/3.73

356,136

288.47/262.74

2

13,071

7.94/7.94

70,075

210.46/210.46

Was there a difference in ARNP malpractice rates in Florida compared to states

demographically similar to Florida but that allow ARNP controlled substance prescribing?
Two criteria were used to compare states that were demographically similar to Florida, the state
population size and number of uninsured residents. From this criteria, three states were found
comparable to Florida; Illinois, New York, and Texas. The following table provides a
comparison of the states, controlled substance prescribing authority and individual malpractice
rates.
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Table 5: ARNP Malpractice Rate Comparisons to Florida
State

Population Size

Prescriptive Authority

18,029,897

Number of
State
Uninsured
3,738,230

Florida

Illinois

12,642,143

1,737,876

Partial Controlled
Substance Prescribing

3.78

New York

19,046,037

2,590,364

Full Controlled
Substance Prescribing

5.28

Texas

23,406,068

5,832,884

Partial Controlled
Substance Prescribing

8.47

No Controlled
Substance Prescribing

ARNP
Malpractice
Rate/1000
14.24

Table 5 indicates that ARNPs with full and partial prescribing authority in states that are
demographically similar have lower malpractice rates compared to Florida which does not allow
controlled substance prescribing.
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CHAPTER 5: DISCUSSION

ARNPs have been providing cost-effective, comparable care for over forty years. This
study was completed to evaluate malpractice rates in states where ARNPs have full prescriptive
authority to those ARNPs with limited or no prescriptive authority to demonstrate that there was
no increased risk of malpractice to the ARNP or the physician when allowing ARNPs to
prescribe controlled substances.
The average or mean rate of malpractice among ARNPs and physicians varied by state
and by discipline. Average or mean malpractice rates for every 1000 physicians varied between
94.27 (Alabama) and 486.72 (Montana) with Mdn = 247.75. Malpractice rates for every 1000
ARNPs varied between zero (Hawaii and Vermont) and 26.56 (New Mexico) with Mdn = 5.28.
This data was included to provide a baseline for the results of the questions that followed. There
are several possible explanations for the variance. Laws in each state regarding malpractice were
not evaluated for this study, but could have an impact on the overall rate. ARNPs have not been
in practice as long as physicians and do not typically provide care in some settings that pose
greater risks for lawsuits (such as a neurosurgery, high-risk obstetrics, etc.). This may partially
explain the disparity between ARNP malpractice rates and physician malpractice rates.
There are 34 states that allow ARNPs full controlled substance prescriptive authority. In
states where ARNPs are allowed to fully prescribe, physicians had no significant difference in
malpractice claims as compared to physicians in states where ARNPs are not allowed to fully
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prescribe. This is significant in that the Florida state legislature has had concerns that ARNPs
who were able to fully prescribe controlled substances would increase the supervising
physician’s malpractice rates. This study does not support that finding. In the fifteen states that
allow ARNPs partial controlled substance prescriptive authority, the findings again concurred
that there was no increase in physician malpractice rates. ARNPs in states with partial controlled
substance prescriptive authority had the lowest malpractice rates overall (4.48/1000 ARNPs), but
not significantly different from ARNPs in states with full prescriptive authority (7.00/1000
ARNPs) or the national mean (6.29/1000 ARNPs). This is noteworthy in that it appears that
increasing the scope of practice by allowing ARNPs to prescribe controlled substances will not
likely increase the supervising physician’s liability, nor the ARNPs liability.
In reviewing the two states that do not have any level of controlled substance
prescribing, the malpractice rate for physicians and ARNPs are higher than in states with partial
or full controlled substance prescriptive authority, although not significantly. One possible
explanation for the higher malpractice rates are the state rules surrounding controlled substance
prescribing. For example, ARNPs who do not have the ability to write for a controlled substance
when one is clearly indicated potentially can be accused of delay of care, or inappropriate
treatment because the most appropriate medication cannot be prescribed. If the physician is not
at the site of service, the patient is frequently asked to secure another appointment to see the
physician so that they can evaluate the patient and prescribe the medication. In this situation,
care has been delayed.
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The disparity of the number of states with full prescribing (34), partial prescribing (15)
and no controlled substance prescribing (2) may have abnormally skewed the data. Florida
ARNPs alone had more malpractice claim reports (M = 14.24) than any other state, and twice the
number as the next highest state (Texas M = 8.47). There is no data base available which looks
specifically at malpractice claims related to controlled substance prescribing. What can be shown
is that ARNPs who have the authority to prescribe controlled substances show no greater
preponderance for having a lawsuit brought against them than ARNPs without controlled
substance prescribing.
To provide a comparison to the NPDB information, data was also gathered from the
HIPDB. In comparing the three groups of states, those with full, partial and no controlled
substance prescriptive authority, ARNPs in those states with no controlled substance prescribing
had considerably more adverse actions, civil judgments, and criminal convictions than ARNPs in
states with partial or full controlled substance prescriptive authority. Specifically, however,
Alabama had the greatest number of HIPDB reports (175) compared to Florida (42). Florida’s
individual number of HIPDB reports was not much different from other states regardless of
prescribing privileges. In evaluating physician adverse actions, criminal convictions and civil
judgments, there were no significant differences throughout the United States, regardless of
ARNP prescribing authority.
As noted above, there are several factors which could contribute to malpractice rates. The
final evaluation was to see if states that were demographically similar to Florida had similar
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malpractice rates. Three states were chosen that most closely matched Florida in terms of total
state resident population and number of persons uninsured. States that were demographically
similar included Illinois, New York and Texas with Illinois and Texas allowing partial
prescriptive authority and New York allowing full prescriptive authority. The results show that
malpractice rates for ARNPs remain appreciably lower in states demographically similar to
Florida even when allowed partial or full prescriptive authority.
There are several limitations to this study and the interpretation of the data. The National
Practitioner Data Bank requires mandatory reporting for MDs and DOs but voluntary reporting
for ARNPs. This could lessen the accuracy of the data. In addition, there is no data set available
which looks specifically at malpractice claims related to controlled substance prescribing.
Developing a monitoring tool to track malpractice claims as they are related to controlled
substance prescribing would provide the State of Florida with accurate information regarding the
nature of the malpractice (inappropriate dose prescribed, adverse outcome, drug trafficking, etc)
and provide information to use to address inappropriate prescribing.
In conclusion, there are currently 48 states and the District of Columbia that allow some
form of controlled substance prescribing. No state has ever rescinded a law granting ARNP
controlled substance prescribing. There have been many studies which show that ARNPs provide
care comparable to physicians, and that overall, ARNPs prescribe less medications than
physicians (Haider, 2008, Horrocks, 2002; Brown and Grimes, 1995). In December, 2008, the
Florida Senate’s Committee on Health Regulation was given a recommendation based on
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extensive study to grant controlled substance prescribing authority to Florida licensed ARNPs
who have attained national certification. One senator again brought up the safety of ARNPs
prescribing controlled substances and directly asked about malpractice rates in other states that
allow ARNPs this authority. This study showed that there is no increase in malpractice rates,
adverse actions, criminal convictions or civil judgments in states where ARNPs prescribe
controlled substances, either fully or partially, supporting the hypothesis. In fact, states that do
not have controlled substance prescriptive authority have increased malpractice rates or
increased criminal convictions, civil judgments, and adverse actions than states that do not.
There are two implications for this study. This study has implications for nursing practice
in that ARNPs who are allowed to prescribe fully can provide comprehensive, cost-effective care
(Kaplan & Brown, 2004). Patients who can be treated fully by ARNPs spend less time in the
office and have less return visits to have their needed prescriptions (Chandler, 2007). This study
also shows the need for a comprehensive data base that tracks specifically controlled substance
errors. There are other tracking systems including the Health Integrity Protection Data Bank, and
this does delineate medication errors, but does not separate RN medication errors from ARNP
prescribing errors. In addition, national requirements for mandatory reporting to the National
Practitioner Data Bank for all providers would help to provide more accurate data.
Recommendations for future studies would include a concurrent study in a controlled
setting, such as a healthcare facility, to monitor ARNP and physician controlled substance

34

prescribing errors to compare to the national NPDB rates. This would provide more accurate data
of the state of controlled substance prescribing errors.
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APPENDIX: NOT HUMAN RESEARCH DETERMINATION
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University of Central Florida Institutional
Review Board
NOT HUMAN RESEARCH DETERMINATION

Office of Research & Commercialization

From :

UCF Institutional Review Board #1
FWA00000351, IRB00001138

To

Deborah C. Chandler, ARNP

:

Date : February 4, 2010
Dear Researcher:
Thank you for sending the description of your proposed research to the IRB office. After reviewing this
information and discussing your plans on the phone, the IRB determined that the following proposed
activity is not human research as defined by DHHS regulations at 45 CFR 46 or FDA regulations at 21
CFR 50/56:
Type of Review:
Project:

Investigator:
Research ID:

Not Human Research Determination
Analysis of nurse practitioner and physician
malpractice in all fifty states – publically available
data, as well as previously published in medical
journals; no personal identifiers.
Deborah Chandler
N/A

University of Central Florida IRB review and approval is not required. This determination applies only to
the activities described in the IRB submission and does not apply should any changes be made. If changes
are to be made and there are questions about whether these activities are research involving human
subjects, please contact the IRB office to discuss the proposed changes.
On behalf of the IRB Chair, Joseph Bielitzki, DVM, this letter is signed by:
Joanne Muratori
IRB Coordinator
cc: Dr. Elizabeth Rash
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